External Link - Source: The New York Times
Last month, the DNA-testing company 23andMe secured Food and Drug Administration approval for a new screening for gene-based health risks. Along with celiac disease, Alzheimer’s, Parkinson’s, breast cancer and several other medical conditions, the company can now screen clients for two mutations that have been linked to colorectal cancer.
But “F.D.A.-approved” does not necessarily mean “clinically useful.” 23andMe relies on much simpler technology than tests that you’d get at your doctor’s office. As a result, the company’s tests cannot tell you much about your actual risk of developing the diseases in question.